IBT has U.S. IND open and Swedish CTA approved for clinical study

IBT announces today that the IND (Investigational New Drug) for the prevention of necrotizing enterocolitis (NEC), has been accepted by the FDA (U.S. Food and Drug Administration). Furthermore, IBT has received approval from the MPA (Medical Product Agency) to conduct its clinical trial in Sweden.

Read the official IBT press release here
Read the official BioGaia press release here

January 8, 2016